HNGE — Q4 FY25 Earnings Review (Bear)

Date: 2026-02-12 (updated from 2026-02-11) Persona: Bear (PaulWBryant) Corpus: No prior writings on HNGE. Applying framework fresh. Sources: Q4 FY25 earnings release, Q4 FY25 Investor Presentation

Prior Beliefs (Going Into Q4 FY25)

I would have expected:

• Revenue around $160-165M, given Q3's $154.2M and the sequential cadence
• Continued 50%+ YoY growth, but starting to decelerate given the law of large numbers
• Gross margins holding ~82%
• Progress toward Non-GAAP profitability, maybe breakeven-ish
• Client adds in the 200+ range
• Billings growth at least matching revenue growth

Updated Beliefs (What Actually Happened)

Every single metric exceeded what I would have expected. That doesn't happen often. And the investor deck filled in the gaps I was worried about.

The Numbers Table

Three consecutive beats of $12-14M. That's not luck. That's either conservative guidance or genuine demand outperformance. Probably both.

What I Like

1. NRR now disclosed: >110%. This was my #2 concern in the original review. The investor deck confirms net dollar retention >110% as of December 31, 2025. Combined with 97% client retention and 100% partner retention, the expansion/retention picture is quantified and strong. This is exactly what I wanted to see.

2. Billings growing faster than revenue. LTM billings at $671M growing 44% YoY vs. revenue at 46%. That's roughly in line, which means the demand pipeline is keeping pace. Deferred revenue jumped from $218M to $301M year-over-year — that's contracted future revenue sitting on the balance sheet.

3. The profitability inflection is real. Non-GAAP operating margin went from negative 7% for FY24 to positive 20% for FY25. Q4 alone was 28%. FCF margin of 36% in Q4, 31% for the full year. For a company growing 50%, that's remarkable. Rule of 40 score of 81. Heck.

4. Already near target operating model. The investor deck shows long-term targets of 82-85% gross margin, 25%+ operating margin, ~30% FCF margin. FY25 delivered 83% GM, 20% op margin, 31% FCF margin. They're essentially already there, with growth still at 50%+. That's unusual — most companies trade off growth for margins. Hinge is getting both.

5. Yield expansion. Annual yield (members / eligible lives) went from 3.4% to 3.9%. That means Hinge is getting better at converting contracted lives into actual enrolled members. That's the land-and-expand working within existing clients, and it's the most capital-efficient growth you can get.

6. Massive whitespace. 24.6M contracted lives out of ~215M addressable lives in existing markets = 90%+ whitespace remaining. They've barely scratched the surface. And that's before international, Medicaid, or traditional Medicare.

7. No debt, $479M in liquidity, buying back stock. Zero debt. $250M buyback authorized, $65M already deployed. For a company that just IPO'd in May 2025, this signals management confidence in cash generation durability. They're not hoarding cash "just in case" — they're returning it.

8. Client adds accelerating. 270 net adds in Q4, up from 201 in Q3 and 103 in Q2. That seasonal pattern makes sense (Q4 is enrollment season for employer benefits), but the absolute number is the highest on record. Win rate at all-time high. "Meaningful number" of competitive conversions.

9. Operating leverage across all expense lines. Non-GAAP S&M dropped from 42% to 35% of revenue. R&D from 25% to 15%. G&A from 17% to 12%. That's ~2,700 bps of total opex leverage in one year. The AI-powered care model is working — 97% reduction in human care team hours vs traditional PT.

10. Robin AI assistant working. 92% thumbs-up rating for AI conversations, higher response rates than human care team. This is how they're scaling care delivery without scaling headcount linearly.

What Gives Me Pause

1. The FY26 guide implies meaningful deceleration. $732-742M at the midpoint is ~25% YoY growth. Coming off 51% in FY25, that's a significant step-down. Now, Hinge has beaten every quarter by $12-14M, so the real number is probably $770-790M (30-35% growth). But the guide itself is a signal that management sees the growth rate normalizing. The numbers have to match the theory — and the theory going forward is 25-30% growth, not 50%.

2. YoY revenue growth is decelerating. 55% → 53% → 46%. That's natural at this scale, but the trajectory matters. If Q1 FY26 comes in at $172M (midpoint of guide), that's 39% YoY. By Q4 FY26, if they hit the annual guide, we're looking at ~25% YoY. That's a company transitioning from hyper-growth to merely fast growth.

3. HingeSelect won't matter until 2027. Management explicitly said the new product won't generate material revenue until at least 2027. The 85% conservative care rate is encouraging, but it's early days. The near-term growth story is entirely about the existing MSK platform and penetration of the employer market.

4. SBC is elevated. FY25 GAAP SBC was 643M, dominatedbytheQ2IPOcharge.Run − rateSBCis 33M/quarter or ~$132M annually on $588M revenue = ~22% of revenue. That's on the high side but not unusual for a recently-IPO'd company. Worth monitoring as the company matures.

5. Small market cap, recent IPO. At 2.8Bmarketcap(pre − AHmove), thisisasmallcompany.Theafter − hourspopto 37.76 (+14%) takes it to roughly $3.2B. That's still small. Small can be good — more room to grow — but it also means less institutional coverage, wider spreads, and more volatility. I'd want to see this prove itself over 4-6 quarters before building real conviction.

Valuation

Here's where it gets interesting. At $33 (close), using FY25 actuals:

Applying my revenue-PEG heuristic: ~46% growth at 4.8x P/S. The growth rate is ten times the P/S multiple. That almost never happens with companies executing this well. Even at the after-hours price of $37.76, you're looking at ~5.5x P/S on trailing and ~4.3x on forward. For a company with 80%+ gross margins, 30%+ FCF margins, >110% NRR, and 25-45% revenue growth depending on how you measure it, this is genuinely cheap.

For context, most SaaS companies growing 25-30% trade at 8-12x P/S. Hinge is growing faster and trading at half that multiple. The market is either skeptical about durability or simply hasn't caught up to the story yet.

The Big Question

Is this a durable growth business or a one-trick pony that saturates its TAM?

The bull case: MSK is a $661B annual cost to employers (per Health Advances). Hinge has ~25M contracted lives out of hundreds of millions of potential lives. Yield is only 3.9% — meaning 96% of contracted lives haven't enrolled yet. The expansion runway within existing clients alone is enormous before you even count new client wins. >110% NRR proves the land-and-expand is working. 97% client retention means they're sticky.

The bear case (no pun intended): Employer benefits decisions are lumpy and cyclical. If the economy weakens, HR budgets get cut. Competition from incumbents (UnitedHealth, Teladoc) could intensify. And the 25% FY26 guide might be the beginning of a long deceleration, not conservative sandbagging.

My Take

I haven't written about this one before, so let me be clear: I don't have conviction yet. Three quarters of public data is not enough for me to build a full position. "Don't let enthusiasm get ahead of conviction."

But the numbers are compelling. A company growing 45-50% with 28% Non-GAAP operating margins, 36% FCF margins, >110% NRR, 97% client retention, zero debt, buying back stock, and trading at under 5x P/S? The numbers match the theory, and then some. The valuation gives you a significant margin of safety even if growth decelerates to 25%.

The investor deck resolved my biggest concern — the NRR disclosure. >110% is solid. Not spectacular (I'd love to see 120%+), but solid. Combined with 97% client retention, the retention/expansion picture is now quantified and it's good.

If I were building a position, I'd start small — maybe 3-5% — and watch Q1 FY26 closely. The key things I'd be looking for:

1. Does Q1 revenue come in above $180M? (That would suggest the guide is sandbagged)
2. Does yield continue expanding above 4%?
3. Do client net adds hold above 200?
4. Does NRR hold above 110%?

If those check out, I'd add. If growth decelerates faster than the guide implies, I'd hold what I have and reassess.

The after-hours move of +14% tells me the market agrees this was a strong quarter. But I don't chase. I'd rather buy on a pullback with more data than pay up on excitement.

I could be wrong. Three quarters is not a track record. But the combination of growth, profitability, retention, and valuation here is unusual. Most companies give you two of those four. Hinge is giving you all four.

Bear